Crossref
4117eP Patient-reported experience of switching from reference to biosimilar denosumab in oncology: A Canadian survey
Annals of Oncology · 2026-12 · 37 · S2106
DOI: 10.1016/j.annonc.2026.08.4366 ↗Kurz gefasst
Fachartikel in der Zeitschrift Annals of Oncology, 2026-12. Verfasst von K. Jerzak und 6 weiteren Autor:innen.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Zitieren
APA
Jerzak, K., Hamilou, Z., Leigh, J., Jagodic, S., Howe, S., Reinbold, A., & Katzenberger, B. (2026). 4117eP Patient-reported experience of switching from reference to biosimilar denosumab in oncology: A Canadian survey. Annals of Oncology, 37, S2106. https://doi.org/10.1016/j.annonc.2026.08.4366
Vancouver
Jerzak K, Hamilou Z, Leigh J, Jagodic S, Howe S, Reinbold A, et al. 4117eP Patient-reported experience of switching from reference to biosimilar denosumab in oncology: A Canadian survey. Annals of Oncology. 2026;37:S2106. doi:10.1016/j.annonc.2026.08.4366
BibTeX
@article{Jerzak2026,
author = {Jerzak, K. and Hamilou, Z. and Leigh, J. and Jagodic, S. and Howe, S. and Reinbold, A. and Katzenberger, B.},
title = {4117eP Patient-reported experience of switching from reference to biosimilar denosumab in oncology: A Canadian survey},
journal = {Annals of Oncology},
year = {2026},
volume = {37},
pages = {S2106},
doi = {10.1016/j.annonc.2026.08.4366}
}
EUVIMED